The estimated Net Worth of Rachel Mc Minn is at least $899 Thousand dollars as of 2 October 2017. Rachel Minn owns over 283 units of Intercept Pharmaceuticals Inc stock worth over $320,625 and over the last 11 years Rachel sold ICPT stock worth over $578,193.
Rachel has made over 18 trades of the Intercept Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Rachel sold 283 units of ICPT stock worth $16,666 on 2 October 2017.
The largest trade Rachel's ever made was selling 816 units of Intercept Pharmaceuticals Inc stock on 3 January 2017 worth over $84,799. On average, Rachel trades about 183 units every 40 days since 2014. As of 2 October 2017 Rachel still owns at least 16,875 units of Intercept Pharmaceuticals Inc stock.
You can see the complete history of Rachel Minn stock trades at the bottom of the page.
Rachel's mailing address filed with the SEC is C/O INTERCEPT PHARMACEUTICALS, INC., 450 W. 15TH STREET, SUITE 505, NEW YORK, NY, 10011.
Over the last 12 years, insiders at Intercept Pharmaceuticals Inc have traded over $1,530,243,701 worth of Intercept Pharmaceuticals Inc stock and bought 2,408,920 units worth $77,118,364 . The most active insiders traders include Srinivas Akkaraju, Jonathan Silverstein, and Francesco Micheli. On average, Intercept Pharmaceuticals Inc executives and independent directors trade stock every 10 days with the average trade being worth of $1,114,673. The most recent stock trade was executed by Srinivas Akkaraju on 10 March 2021, trading 237,000 units of ICPT stock currently worth $5,017,290.
we are a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive, non-viral liver diseases, including primary biliary cholangitis (pbc), nonalcoholic steatohepatitis (nash), primary sclerosing cholangitis (psc) and biliary atresia. in a new age of liver disease treatment, our team is developing vital therapies to meet the needs of those living with progressive, non-viral liver disease. we are committed to improving patients’ lives and addressing the liver community’s most pressing needs. our corporate headquarters is located in new york, and we have additional offices in san diego, london and perugia. for more information about intercept, please visit our website at: www.interceptpharma.com and follow us on twitter at: @interceptpharma.
Intercept Pharmaceuticals Inc executives and other stock owners filed with the SEC include: